Who can use Dacomitinib(Vizimpro)?

VIZIMPRO is indicated for the first-line treatment of metastatic non-small cell lung cancer harboring specific EGFR mutations.

Approved Use

This medication is prescribed for patients with metastatic non-small cell lung cancer whose tumors have been confirmed to carry either an EGFR exon 19 deletion or an exon 21 L858R substitution mutation. It is intended for use as an initial treatment option following mutation detection through an FDA-approved diagnostic test.